STAT

NOVEMBER 12, 2023

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease. Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of

331

331

Safe Biologics

NOVEMBER 12, 2023

ASBM Whitepaper to Examine Impact of Medicare Drug Price-Setting on Drug Development, Patient Access The Journal of the Generics and Biosimilars Initiative (GaBI) is currently finalizing a whitepaper based on the July 26th webinar hosted by ASBM and GaBI entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

STAT

NOVEMBER 12, 2023

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients. Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen P

311

311

Safe Biologics

NOVEMBER 12, 2023

On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer. The policy change represents a stark departure from the perspectives of the U.S. medical community and patient advocacy organizations, a decade of state-level policymaking

Biosimilars 113

Biosimilars 113

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Patent Watch

NOVEMBER 12, 2023

In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending… The post AI-Driven Strategies: Pharma’s Answer to Patent Expirations appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 109

Pharmaceutical Companies Pharmaceutical Companies 109

Express Pharma

NOVEMBER 12, 2023

Zydus Lifesciences was able to successfully launch its homegrown NCE drugs Oxemia (desidustat) and Lipaglyn (saroglitazor) in the Indian market. It also partnered with Sun Pharma and Lupin to co-market desidustat and saroglitazar, respectively, in the Indian market. These partnerships will help improve the market penetration of these drugs in India, says GlobalData.

Diabetes 95

Diabetes 95

pharmaphorum

NOVEMBER 12, 2023

AHA: Wegovy improves survival in outcomes trial Phil.

108

108

Drug Patent Watch

NOVEMBER 12, 2023

Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmacy Joe

NOVEMBER 12, 2023

In this episode, I’ll discuss haloperidol for ICU delirium. Episode 869: Three Recent Studies About Haloperidol and ICU Delirium Subscribe on iTunes , Android , or Stitcher Despite efforts to reduce the incidence of ICU delirium with light sedation techniques, many patients still end up with delirium during their stay in the ICU. Some of these patients develop agitated delirium that requires treatment so the patient does not harm themselves or staff caring for them.

Hospitals 52

Hospitals Inpatient Labelling 52

Drug Patent Watch

NOVEMBER 12, 2023

Annual Drug Patent Expirations for SKYLA Skyla is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug SKYLA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma in Brief

NOVEMBER 12, 2023

The Patented Medicine Prices Review Board ( PMPRB ) has released a scoping paper on themes and questions to develop new price review Guidelines. The scoping paper also includes information on how stakeholders can participate in the consultation. The deadline for written submissions addressing the scoping paper is December 20, 2023. Background The PMPRB has not had a full set of Guidelines since July 1, 2022, when amendments to the Patented Medicines Regulations came into force implementing a

Drug Pricing 52

Drug Pricing Documentation 52

Drug Patent Watch

NOVEMBER 12, 2023

Annual Drug Patent Expirations for KYLEENA Kyleena is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are six patents… The post New patent expiration for Bayer Hlthcare drug KYLEENA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Med Ed 101

NOVEMBER 12, 2023

In this case scenario, I review the possibility of venlafaxine withdrawal and some key factors that lead me to this assessment. A 59-year-old patient presents to your pharmacy seeking a refill for her Klonopin prescription and to purchase a pill organizer for herself. Upon discussing with her, she reports a slight fever, chills, and fatigue […] The post Venlafaxine Withdrawal – Case Study appeared first on Med Ed 101.

52

52

Drug Patent Watch

NOVEMBER 12, 2023

AMRIX (cyclobenzaprine hydrochloride) Teva pharms intl Patent: 7,829,121 Expiration: Nov 14, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of November 12, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmacy Times

NOVEMBER 12, 2023

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

58

58

Drug Patent Watch

NOVEMBER 12, 2023

This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Business Review

NOVEMBER 12, 2023

A clinical stage pipeline asset for the company , LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD. Earlier, LP-10 received ODD from the FDA, thereby making LP-310 the second of the company’s leading product candidates to receive this designation. LP-310 liposomal tacrolimus is an oral rinse formulation of the company’s lead drug candidate, LP-10.

Immunity 59

Immunity Immunization 59